Post-Traumatic Stress Disorder Pipeline Outlook Report 2025: Promising Drugs and MOA Innovations Reshape Future Treatment Approaches | DelveInsight

DelveInsight's "Post-Traumatic Stress Disorder Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Post-Traumatic Stress Disorder pipeline landscape. It covers the Post-Traumatic Stress Disorder Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Post-Traumatic Stress Disorder Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Post-Traumatic Stress Disorder Pipeline? Click here to explore the therapies and trials making headlines @ Post-Traumatic Stress Disorder Pipeline Outlook Report [https://www.delveinsight.com/sample-request/post-traumatic-stress-disorder-ptsd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Post-Traumatic Stress Disorder Pipeline Report

* On 25 November 2025, Transcend Therapeutics conducted a study is evaluating the safety and efficacy of methylone in adults with PTSD. The study is conducted in two parts. Part A is open-label and will enroll up to 15 participants with PTSD. Part B is randomized (1:1:1), single-blind and will enroll up to 45 participants with PTSD Eligible participants will enter a 3-week Treatment Period (Part A) or 4-week Treatment Period (Part B) where they will receive methylone once weekly. Following the Treatment Period, participants will enter a 6-week Follow-up Period (Part A) or 8-week Follow-up Period (Part B).
* On 21 November 2025, Otsuka Medical Devices Co., Ltd . Japan announced a study to Assess Efficacy and Safety of Software as a Medical Device in Patients With Post-Traumatic Stress Disorder (PTSD).
* DelveInsight's Post-Traumatic Stress Disorder Pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Post-Traumatic Stress Disorder treatment.
* The leading Post-Traumatic Stress Disorder Companies such as Tonix Pharmaceuticals, Inc., Pop Test Oncology LLC, H. Lundbeck A/S, Bionomics Limited, Alto Neuroscience, Transcend Therapeutics and others.
* Promising Post-Traumatic Stress Disorder Therapies such as Sertraline and Risperidone, Balovaptan, Brexpiprazole, Risperidone, Psilocybin, JZP150 , and others.

Want to know which companies are leading innovation in Post-Traumatic Stress Disorder? Dive into the full pipeline insights @ Post-Traumatic Stress Disorder Clinical Trials Assessment [https://www.delveinsight.com/sample-request/post-traumatic-stress-disorder-ptsd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Post-Traumatic Stress Disorder Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Post-Traumatic Stress Disorder Pipeline Report also highlights the unmet needs with respect to the Post-Traumatic Stress Disorder.

Post-Traumatic Stress Disorder Overview

Post-traumatic stress disorder (PTSD) is a disabling psychiatric disorder that results from being exposed to real or threatened injury, death, and assault. It is associated with functional and cognitive impairment. Early diagnosis and intervention are necessary for effective treatment and to minimize the long-term outcomes associated with PTSD. PTSD is a disorder that develops in some people who have experienced a shocking, scary, or dangerous event. It is natural to feel afraid during and after a traumatic situation. Fear is a part of the body's "fight-or-flight" response, which helps us avoid or respond to potential danger. People may experience a range of reactions after trauma, and most people recover from initial symptoms over time. Those who continue to experience problems may be diagnosed with PTSD. Anyone can develop PTSD at any age. This includes combat veterans and people who have experienced or witnessed a physical assault, abuse, an accident, a disaster, or other serious events. People who have PTSD may feel stressed or frightened, even when they are not in danger.

Post-Traumatic Stress Disorder Emerging Drugs Profile

* TNX-102: Tonix Pharmaceuticals, Inc.

TNX-102 SL is a small, rapidly-disintegrating, under the tongue (sublingual) product candidate containing cyclobenzaprine HCl. The unique patented formulation has been designed to optimize the delivery and absorption of cyclobenzaprine for the therapeutic benefit of improving sleep quality, while minimizing the potential residual effects of oral formulations of cyclobenzaprine. As a multifunctional agent with potent binding and antagonist activities at the serotonin2A, 1-adrenergic, histaminergic-H1, and muscarinic-M1 receptors, TNX-102 SL is in clinical development and has active IND's as a daily bedtime treatment for fibromyalgia, PTSD, alcohol use disorder and agitation in Alzheimer's disease (AAD). TNX-102 SL for AAD has been designated by the FDA a Fast Track development program. Currently, the drug is in phase III stage for the treatment of post-traumatic stress disorder.

* Methylone (TSND-201): Transcend Therapeutics

Methylone, identified as a rapid-acting neuroplastogen, has been shown to swiftly trigger the expression of neuroplasticity genes, including BDNF, in brain regions associated with the pathophysiology of conditions like PTSD, depression, and other central nervous system disorders. This effect is particularly significant given the challenges posed by PTSD, MDD, and anxiety, which stem from deficiencies in the brain circuitry responsible for emotional learning and processing. Currently, the drug is in Phase II stage of its clinical trial for the treatment of PTSD.

* BXCL501: BioXcel Therapeutics

BXCL501, developed by BioXcel Therapeutics, is an innovative neuroscience clinical asset with a novel mechanism of action targeting symptoms like agitation. This investigational, proprietary, orally dissolving film formulation contains dexmedetomidine, a selective alpha-2 receptor agonist. BXCL501 aims to address stress-related behaviors such as agitation and has shown promising anti-agitation results in various clinical trials across neuropsychiatric disorders. Currently, the drug is in Phase I stage of its clinical trial for the treatment of PTSD.

If you're tracking ongoing Post-Traumatic Stress Disorder Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Post-Traumatic Stress Disorder Treatment Drugs [https://www.delveinsight.com/sample-request/post-traumatic-stress-disorder-ptsd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Post-Traumatic Stress Disorder Pipeline report provides insights into:-

* The report provides detailed insights about companies that are developing therapies for the treatment of Post-Traumatic Stress Disorder with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Post-Traumatic Stress Disorder Treatment.
* Post-Traumatic Stress Disorder Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Post-Traumatic Stress Disorder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Post-Traumatic Stress Disorder market.

Post-Traumatic Stress Disorder Companies

Tonix Pharmaceuticals, Inc., Pop Test Oncology LLC, H. Lundbeck A/S, Bionomics Limited, Alto Neuroscience, Transcend Therapeutics and others.

Post-Traumatic Stress Disorder Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

Post-Traumatic Stress Disorder Products have been categorized under various Molecule types such as,

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

From emerging drug candidates to competitive intelligence, the Post-Traumatic Stress Disorder Pipeline Report covers it all - check it out now @ Post-Traumatic Stress Disorder Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/post-traumatic-stress-disorder-ptsd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Post-Traumatic Stress Disorder Pipeline Report

* Coverage- Global
* Post-Traumatic Stress Disorder Companies- Tonix Pharmaceuticals, Inc., Pop Test Oncology LLC, H. Lundbeck A/S, Bionomics Limited, Alto Neuroscience, Transcend Therapeutics and others.
* Post-Traumatic Stress Disorder Therapies- Sertraline and Risperidone, Balovaptan, Brexpiprazole, Risperidone, Psilocybin, JZP150 , and others.
* Post-Traumatic Stress Disorder Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Post-Traumatic Stress Disorder Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research - discover what's next for the Post-Traumatic Stress Disorder Treatment landscape in this detailed analysis @ Post-Traumatic Stress Disorder Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/post-traumatic-stress-disorder-ptsd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Post-traumatic Stress Disorder (PTSD) : Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Post-traumatic Stress Disorder (PTSD) - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* TNX-102: Tonix Pharmaceuticals, Inc.
* Mid Stage Products (Phase II)
* Methylone (TSND-201): Transcend Therapeutics
* Early Stage Products (Phase I)
* BXCL501: BioXcel Therapeutics
* Comparative Analysis
* Post-traumatic Stress Disorder (PTSD) Key Companies
* Post-traumatic Stress Disorder (PTSD) Key Products
* Post-traumatic Stress Disorder (PTSD) - Unmet Needs
* Post-traumatic Stress Disorder (PTSD) - Market Drivers and Barriers
* Post-traumatic Stress Disorder (PTSD) - Future Perspectives and Conclusion
* Post-traumatic Stress Disorder (PTSD) Analyst Views
* Post-traumatic Stress Disorder (PTSD) Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=posttraumatic-stress-disorder-pipeline-outlook-report-2025-promising-drugs-and-moa-innovations-reshape-future-treatment-approaches-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/post-traumatic-stress-disorder-ptsd-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.